4 recruiting, 2 active not recruiting, 2 unknown, 1 not yet recruiting. 3 Phase 2, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow PARP Inhibitor: new trials by email Literature Review of PARP Inhibitor trials Research Report on PARP Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors SRP1020 - Advanced Solid Tumors, PARP Inhibitor | Phase 1 / Phase 2 | Recruiting | Shanghai SciBrunch Therapeutics Co., Ltd. | 210 | 2026-01-08 | 2026-02-05 |
| The HER Project: HRD in EGFR-mutated NSCLC No Intervention: Observational Cohort - EGFR, Non Small Cell Lung Cancer | Active not recruiting | IRCCS San Raffaele | 100 | 2025-12-01 | 2025-12-31 | |
| REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors REVITALIZE Intervention, Educational Materials - Ovarian Cancer, Advanced Ovarian Carcinoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 240 | 2025-03-17 | 2026-04-13 |
| PARPi and Ovarian Cancer Survival Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, PARP Inhibitor | Not yet recruiting | Shanghai Gynecologic Oncology Group | 6000 | 2025-03-01 | 2025-02-20 | |
| Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients) - Breast Cancer, Familial Male, Radiotherapy; Complications | Not applicable | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 148 | 2024-01-12 | 2024-08-21 |
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Vismodegib, Atezolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | Recruiting | Ronald Buckanovich | 48 | 2023-05-15 | 2026-06-18 |
| Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients PARP inhibitor - Ovarian Cancer, HRD | Unknown | Xiaoxiang Chen | 100 | 2021-09-15 | 2021-09-14 | |
| The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer PARP inhibitors - Ovarian Cancer, Clinical Marker | Unknown | Xiaoxiang Chen | 60 | 2020-12-15 | 2021-01-20 | |
| Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy) - Malignant Gliomas, Radiotherapy | Phase 1 / Phase 2 | Active not recruiting | Centre Francois Baclesse | 91 | 2017-09-04 | 2025-12-04 |
Ovarian Neoplasms (3) · Breast Cancer, Familial Male (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Glioma (1) · Kenny-Caffey syndrome, Type 1 (1)
Neoplasms (7) · Neoplasms by Site (6) · Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Gonadal Disorders (4) · Ovarian Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Neoplasms by Histologic Type (2)
olaparib (3) · Poly(ADP-ribose) Polymerase Inhibitors (2) · niraparib (2) · HhAntag691 (1) · Radiotherapy, Intensity-Modulated (1) · Temozolomide (1) · atezolizumab (1)
Xiaoxiang Chen (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Francois Baclesse (1) · Dana-Farber Cancer Institute (1) · IRCCS San Raffaele (1) · Ronald Buckanovich (1) · Shanghai Gynecologic Oncology Group (1) · Shanghai SciBrunch Therapeutics Co., Ltd. (1)
China (4) · United States (2) · France (1) · Italy (1)
Xiaoxiang Chen, MD,PhD (2) · Alexi A Wright, MD, MPH (1) · Bo Lan, MD (1) · Fei Ma, MD (1) · Francesca Rita Ogliari, Medical Doctor (1) · Jing Ni, MD (1) · Joanna J Arch, PhD (1) · Ronald J Buckanovich, MD (1) · Shulian Wang, MD (1) · Yirui Zhai, MD (1)
PMID 28581356, PMID 28968163, PMID 34081848, PMID 35020465, PMID 35344040, PMID 39882966, PMID 41928160
R01CA289547 (1)